Abvc Biopharma Stock Analysis
| ABVC Stock | USD 0.52 0.02 3.70% |
ABVC Biopharma is overvalued with Real Value of 0.46 and Target Price of 2.02. The main objective of ABVC Biopharma stock analysis is to determine its intrinsic value, which is an estimate of what ABVC Biopharma is worth, separate from its market price. There are two main types of ABVC Biopharma's stock analysis: fundamental analysis and technical analysis.
The ABVC Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ABVC Biopharma's ongoing operational relationships across important fundamental and technical indicators.
ABVC |
ABVC Stock Analysis Notes
About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.48. Some equities with similar Price to Book (P/B) outperform the market in the long run. ABVC Biopharma recorded a loss per share of 0.81. The entity last dividend was issued on the 8th of May 2019. The firm had 1:10 split on the 25th of July 2023. ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation. Abvc Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more info on ABVC Biopharma please contact Howard MD at (510)-668-0881 or go to https://www.abvcpharma.com.ABVC Biopharma Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ABVC Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ABVC Biopharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| ABVC Biopharma generated a negative expected return over the last 90 days | |
| ABVC Biopharma has some characteristics of a very speculative penny stock | |
| ABVC Biopharma has high historical volatility and very poor performance | |
| ABVC Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 152.43 K. Net Loss for the year was (10.52 M) with loss before overhead, payroll, taxes, and interest of (32.89 K). | |
| ABVC Biopharma currently holds about 2.99 M in cash with (4.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying 150,000 in Licensing Fees |
ABVC Biopharma Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ABVC Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
ABVC Largest EPS Surprises
Earnings surprises can significantly impact ABVC Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.05 | -0.06 | -0.01 | 20 | ||
2021-11-15 | 2021-09-30 | -0.04 | -0.07 | -0.03 | 75 | ||
2021-08-12 | 2021-06-30 | -0.04 | -0.08 | -0.04 | 100 |
ABVC Stock Institutional Investors
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Chase Investment Counsel Corp | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 71.6 K | Vanguard Group Inc | 2024-09-30 | 46.9 K | Honkamp Krueger Financial Services Inc | 2024-09-30 | 39 K | Xtx Topco Ltd | 2024-09-30 | 23.4 K | Northern Trust Corp | 19.1 K | State Street Corp | 2024-09-30 | 12.9 K | Two Sigma Securities, Llc | 2024-09-30 | 12.4 K | Tower Research Capital Llc | 2024-09-30 | 2.6 K |
ABVC Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.32 M.ABVC Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.83) | (0.88) | |
| Return On Capital Employed | (1.10) | (1.16) | |
| Return On Assets | (0.83) | (0.88) | |
| Return On Equity | (1.13) | (1.18) |
Management Efficiency
ABVC Biopharma has return on total asset (ROA) of (0.4455) % which means that it has lost $0.4455 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.2036) %, meaning that it created substantial loss on money invested by shareholders. ABVC Biopharma's management efficiency ratios could be used to measure how well ABVC Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of January 31, 2025, Return On Tangible Assets is expected to decline to -0.88. In addition to that, Return On Capital Employed is expected to decline to -1.16. At present, ABVC Biopharma's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 15.5 M, whereas Total Current Assets are forecasted to decline to about 1.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.69 | 1.77 | |
| Tangible Book Value Per Share | 1.69 | 1.77 | |
| Enterprise Value Over EBITDA | (0.80) | (0.84) | |
| Price Book Value Ratio | 0.69 | 0.66 | |
| Enterprise Value Multiple | (0.80) | (0.84) | |
| Price Fair Value | 0.69 | 0.66 | |
| Enterprise Value | 94.5 M | 89.8 M |
The leadership approach at ABVC Biopharma's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Technical Drivers
As of the 31st of January, ABVC Biopharma shows the Market Risk Adjusted Performance of 0.0382, mean deviation of 3.96, and Coefficient Of Variation of 32635.56. ABVC Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.ABVC Biopharma Price Movement Analysis
The output start index for this execution was fourty-four with a total number of output elements of seventeen. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ABVC Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ABVC Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ABVC Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ABVC Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ABVC Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ABVC Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ABVC Biopharma Outstanding Bonds
ABVC Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ABVC Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ABVC bonds can be classified according to their maturity, which is the date when ABVC Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
ABVC Biopharma Predictive Daily Indicators
ABVC Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ABVC Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ABVC Biopharma Forecast Models
ABVC Biopharma's time-series forecasting models are one of many ABVC Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ABVC Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About ABVC Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ABVC Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ABVC shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ABVC Biopharma. By using and applying ABVC Stock analysis, traders can create a robust methodology for identifying ABVC entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (80.38) | (84.40) | |
| Operating Profit Margin | (61.99) | (65.09) | |
| Net Loss | (79.33) | (83.30) | |
| Gross Profit Margin | (0.88) | (0.93) |
Current ABVC Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ABVC analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ABVC analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 2.02 | Hold | 1 | Odds |
Most ABVC analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ABVC stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ABVC Biopharma, talking to its executives and customers, or listening to ABVC conference calls.
ABVC Stock Analysis Indicators
ABVC Biopharma stock analysis indicators help investors evaluate how ABVC Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ABVC Biopharma shares will generate the highest return on investment. By understating and applying ABVC Biopharma stock analysis, traders can identify ABVC Biopharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 1.4 M | |
| Common Stock Shares Outstanding | 4.3 M | |
| Total Stockholder Equity | 8.4 M | |
| Tax Provision | 256 K | |
| Property Plant And Equipment Net | 8.8 M | |
| Cash And Short Term Investments | 139.5 K | |
| Cash | 60.2 K | |
| Accounts Payable | 112.9 K | |
| Net Debt | 2.2 M | |
| 50 Day M A | 0.5382 | |
| Total Current Liabilities | 5.9 M | |
| Other Operating Expenses | 8.4 M | |
| Non Current Assets Total | 12.8 M | |
| Non Currrent Assets Other | 1.5 M | |
| Stock Based Compensation | 1.6 M |
Complementary Tools for ABVC Stock analysis
When running ABVC Biopharma's price analysis, check to measure ABVC Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABVC Biopharma is operating at the current time. Most of ABVC Biopharma's value examination focuses on studying past and present price action to predict the probability of ABVC Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABVC Biopharma's price. Additionally, you may evaluate how the addition of ABVC Biopharma to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |